AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21384253
Drug: Homogenised spinach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homogenised spinach (225 g/day/person)
Trial: 9122358
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral naltrexone
Trial: 2434792
Drug: Cilazapril 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 1.25 mg p.o. q.d.
Trial: 2434792
Drug: Cilazapril 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5.0 mg p.o. q.d.
Trial: 29075824
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bevacizumab and Everolimus (dual-therapy)
Trial: 29075824
Drug: Dual-therapy in
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-therapy in normal liver (Arm E)
Trial: 29075824
Drug: Dual-therapy in
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-therapy in normal liver (Arm B)
Trial: 16882058
Drug: 25 mg/day
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/day naftopidil (Group LD)
Trial: 16882058
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day naftopidil (Group HD)
Trial: 14661012
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1500 mg, starting the evening before angiography and given every 12 hours for 4 doses
Trial: 8795667
Drug: Lysine aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine aspirin 900 mg
Trial: 8795667
Drug: Sodium salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium salicylate 800 mg
Trial: 8795667
Drug: 9.5% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.5% saline with indomethacin 50 mg
Trial: 6600677
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg
Trial: 12421160
Drug: Naproxen 375
RxNorm normalized name: naproxen 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 375 mg
Trial: 30878329
Drug: Standard training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard training plus additional weekly simulation training
Trial: 30878329
Drug: Standard training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard training plus additional weekly simulation training (standardized to supervisor's performance)
Trial: 28366341
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy including parent involved play (CBT-PIP)
Trial: 28366341
Drug: Non-directive treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-directive treatment (TEPT; triadic expressive play therapy)
Trial: 27092916
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injection prior to implant placement
Trial: 27092916
Drug: No Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Botulinum toxin type A injection (Control group)
Trial: 24703078
Drug: BROADLINE(®) at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BROADLINE(®) at 0.12 mg/kg body weight
Trial: 22116799
Drug: Macrolide antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrolide antibiotics (e.g., erythromycin, azithromycin)
Trial: 22116799
Drug: No macrolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No macrolide antibiotics (Control)
Trial: 22116799
Drug: Fluoroquinolone antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone antibiotics (n = 90)
Trial: 22116799
Drug: Cephalosporin antibiotics
RxNorm normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalosporin antibiotics (n = 93)
Trial: 12465006
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (ORIF with IMF and ORIF without IMF)
Trial: 10211915
Drug: Trihexyphenidyl (THP)
DrugBank: Trihexyphenidyl (DB00376)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trihexyphenidyl (THP) dose reduction by 1 mg every 2 weeks
Trial: 10211915
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dose reduction)
Trial: 2371034
Drug: d-fenfluramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (15 mg twice daily)
Trial: 24705623
Drug: Cilostazol and
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol and probucol combination therapy
Trial: 19032525
Drug: Cinacalcet (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (administered for 7-14 months)
Trial: 1984829
Drug: 7-3 therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-3 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3)
Trial: 1984829
Drug: 7-3-7 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-3-7 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3 plus etoposide 75 mg/m2 on days 1 to 7)
Trial: 1984829
Drug: 7-3 therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-3 therapy
Trial: 1984829
Drug: 7-3-7 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-3-7 therapy
Trial: 1984829
Drug: 7-3 therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-3 therapy (subset analysis for patients younger than 55 years)
Trial: 1984829
Drug: 7-3-7 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-3-7 therapy (subset analysis for patients younger than 55 years)
Trial: 32044
Drug: Terfenadine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 20 mg
Trial: 26437449
Drug: Multi-dimensional and
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dimensional and inter-sectoral intervention program including therapy simplification and individualized patient education during hospital stay and up to three months after discharge, with subsequent phone calls after discharge.
Trial: 21883123
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg.kg(‐1)
Trial: 21883123
Drug: Morphine 100
RxNorm normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 100 μg.kg(‐1)
Trial: 19609165
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle (PFM) training for 8 weeks, including 3 sets of daily fast and slow contractions in various positions and weekly motivational calls.
Trial: 17716312
Drug: Sub-antimicrobial dose
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-antimicrobial dose doxycycline (SDD; 20 mg bid)
Trial: 14755150
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication therapy (specifics not provided)
Trial: 14755150
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily for 12 months
Trial: 9853852
Drug: Intramesosalpingeal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramesosalpingeal injection of 20 IU oxytocin diluted to 20 ml with saline solution
Trial: 9853852
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml saline solution (control)
Trial: 2687142
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg at night (single dose)
Trial: 31443993
Drug: Co-Administration group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-Administration group (RZV dose 1 and Tdap at Day 0, RZV dose 2 at Month 2)
Trial: 31443993
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Tdap at Day 0, RZV dose 1 at Month 2, RZV dose 2 at Month 4)
Trial: 31443993
Drug: Co-Administration group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-Administration group and Control group
Trial: 25026944
Drug: Inner relationship
RxNorm normalized name: isosulfan blue inner salt
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inner relationship focusing (20‐h course followed by 5 months of weekly sessions)
Trial: 23625433
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg/d for 5 days
Trial: 17091656
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L‐Pop (APL)
Trial: 11583750
Drug: Radical nephrectomy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical nephrectomy plus interferon-alfa-based immunotherapy (5x10(6) IU/m(2) subcutaneously three times per week)
Trial: 7869303
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pamidronate
Trial: 7869303
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pamidronate
Trial: 2450722
Drug: Prophylactic chemotherapy
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic chemotherapy with 5-FU via the recanalized umbilical vein in patients without liver metastases
Trial: 2450722
Drug: Intraportal adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal adjuvant chemotherapy after resection of liver metastases
Trial: 2450722
Drug: Intraarterial chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial chemotherapy in patients with unresectable liver metastases
Trial: 30249314
Drug: Cottage cheese
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cottage cheese (CC) - 30 g of protein, 10 g of carbohydrate, 0 g of fat
Trial: 25009252
Drug: Tonic pain
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonic pain during locomotor adaptation task (capsaicin cream applied around the ankle) on Day 1
Trial: 12463730
Drug: rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (40 mg once daily)
Trial: 10367540
Drug: Gemcitabine (1.000/1.250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1.000/1.250 mg/m2, administered on days 1, 8, 15 every 4 weeks)
Trial: 7478688
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg/day for 4 weeks, increased to 40 mg if no marked improvement after 4 weeks
Trial: 2110198
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (200 mg orally four times per day)
Trial: 27018464
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of Foley balloon followed by oxytocin
Trial: 24946565
Drug: Tripterygium glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium glycosides (20 mg, three times a day for three months)
Trial: 24946565
Drug: Prednisone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.75 mg kg-1 d-1, gradually reduced to 5 mg d-1)
Trial: 15813763
Drug: Weekly Browsing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly Browsing Journal Club (WBJC)
Trial: 10601505
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily)
Trial: 10601505
Drug: Indinavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir (800 mg every eight hours) plus zidovudine and lamivudine
Trial: 10601505
Drug: Efavirenz plus
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz plus indinavir (1000 mg every eight hours)
Trial: 10601505
Drug: Indinavir and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir and two nucleoside reverse‐transcriptase inhibitors
Trial: 10601505
Drug: Efavirenz and
RxNorm normalized name: Efavirenz and lamivudine and tenofovir only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz and two nucleoside reverse‐transcriptase inhibitors
Trial: 8720308
Drug: Lumbricus spencer,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbricus spencer, single oral dose of 500 mg
Trial: 8720308
Drug: Lumbricus spencer,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbricus spencer, 1500 mg/d for one week
Trial: 3698511
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at incremental rates (4, 10, 25, and 62.5 ng min‐1 kg‐1)
Trial: 3698511
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at highest rate
Trial: 27150080
Drug: Methylphenidate (20
RxNorm normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20 mg oral)
Trial: 24666893
Drug: Basic root
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic root canal treatment (BRT) with tactile working length determination
Trial: 24666893
Drug: Standard endodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard endodontic treatment with radiographic working length control
Trial: 22563844
Drug: Randomized assignment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized assignment to treatment
Trial: 19651669
Drug: Combination (arm-ergometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (arm-ergometry + treadmill)
Trial: 17853009
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day for 1 month
Trial: 15077098
Drug: Ticlopidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine and aspirin
Trial: 12603500
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/day for 12 months
Trial: 1748138
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg hCT
Trial: 1748138
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg hCT
Trial: 6763404
Drug: Antihypertensive pharmacotherapy
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive pharmacotherapy
Trial: 26983164
Drug: Acetaminophen/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/paracetamol
Trial: 16812974
Drug: Simvastatin 20-40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20-40 mg
Trial: 15301218
Drug: Novel oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel oral water irrigator
Trial: 1809419
Drug: Neutral hypnotic
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral hypnotic control condition
Trial: 6218097
Drug: mezlocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin (4 g 6-hourly)
Trial: 6218097
Drug: carbenicillin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbenicillin (5 g 4-hourly)
Trial: 30660371
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of lavender oil
Trial: 28930494
Drug: Momelotinib 200
RxNorm normalized name: momelotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib 200 mg once daily
Trial: 28930494
Drug: Ruxolitinib 20
RxNorm normalized name: ruxolitinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 20 mg twice a day
Trial: 23838316
Drug: OCDC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCDC vaccine (dendritic cells pulsed with HOCl-oxidized autologous tumor lysate)
Trial: 21219979
Drug: Pandemic (H1N1)
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic (H1N1) 2009 vaccine containing 7.5 μg of hemagglutinin (HA)
Trial: 21219979
Drug: Pandemic (H1N1)
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic (H1N1) 2009 vaccine containing 15 μg of hemagglutinin (HA)
Trial: 21219979
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of A H1N1 vaccine
Trial: 21219979
Drug: Pandemic (H1N1)
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic (H1N1) 2009 vaccine formulations
Trial: 19809382
Drug: Chemotherapy-induced relative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-induced relative change signatures (TDelta)
Trial: 12324295
Drug: Flour fortified
RxNorm normalized name: Flours
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flour fortified with iron only (60 mg Fe/kg)
Trial: 12324295
Drug: Flour cofortified
RxNorm normalized name: Flours
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flour cofortified with zinc sulfate (60 mg Zn/kg)
Trial: 12324295
Drug: Flour cofortified
RxNorm normalized name: Flours
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flour cofortified with zinc oxide (60 mg Zn/kg)
Trial: 9880768
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy with radioisotope implantation
Trial: 31194613
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d (neoadjuvant therapy for 42 days; adjuvant therapy for up to 12 months)
Trial: 31194613
Drug: Gemcitabine 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,250 mg/m2 plus cisplatin 75 mg/m2 (neoadjuvant therapy for two cycles; adjuvant therapy for up to two cycles)
Trial: 21521254
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR 20 mg every 28th day for 6 months
Trial: 16925701
Drug: Control eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eye drops (tropicamide, phenylepherine, atropine) administered as routine practice
Trial: 10722780
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (PLA)
Trial: 3979676
Drug: Cimetidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (20 mg/kg/24 h)
Trial: 27224474
Drug: CD64-guided group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD64-guided group (antibiotics prescribed based on CD64 index)
Trial: 27224474
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (antibiotics prescribed based on experience and clinical symptoms)
Trial: 19736368
Drug: Aerosolized L-epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized L-epinephrine
Trial: 11854876
Drug: Heparin-bonded cardiopulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded cardiopulmonary bypass (HB-CPB)
Trial: 7566580
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol (0.045 micrograms/kg/weekly)
Trial: 7566580
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral calcitriol (0.045 micrograms/kg/weekly)
Trial: 7566580
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral calcitriol (0.045 micrograms/kg/weekly)
Trial: 1981436
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin phosphate 1% twice daily
Trial: 1981436
Drug: Oral minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minocycline 50 mg twice daily
Trial: 7029294
Drug: 4 drugs
RxNorm normalized name: copper
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drugs (vincristine, dactinomycin, cyclophosphamide, adriamycin)
Trial: 7029294
Drug: 3 drugs
RxNorm normalized name: goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 drugs (vincristine, dactinomycin, cyclophosphamide)